Anxiety is a result of a combination of biological, psychological, and other individual factors. Neurochemical imbalances in γ-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, and other neurotransmitter pathways in the brain can contribute to the development of anxiety. For example, serotonin appears to be specifically involved in feelings of well-being, and disruption in this pathway is highly related to anxiety and depression. Many physical and emotional factors can induce anxiety, that can be related to substance-induced stimulants or depressants, stress-related anxious feelings or can be health concerns related to medical conditions. People who have been diagnosed with cancer, can experience a spectrum of anxiety disorders. Endogenous CB1/CB2 receptor system plays a key role in regulating pathways related to anxiety and patients with anxiety and mood disorders generally have reduced levels of eCBs.

Current treatments for anxiety are associated with adverse effects and have dependency and withdrawal issues. This has driven us to discover and develop the pharmaceutical formulation (MP-20X) novel prodrug-based API molecules targeting the endocannabinoid system, in an enhanced drug-delivery mechanism, offering great potential in the field of affective disorders, including anxiety and depression.

The COVID-19 pandemic has affected our lives immensely. A significant global population is facing this pandemic related challenge that are very stressful and cause strong emotions that relates to fear and anxiety. With this notion, anxiety and depression issues are at an all-time high and therefore, demand for benzodiazepines such as Valium and Xanax have risen steeply in last 18-24 months. Like benzodiazepines, MP-20X has shown promise to treat anxiety and depression very effectively – the difference is, MP-20X is very safe and that it doesn’t create issues related to dependency and tolerance that exist in current anxiolytic medications on the market.

MP-20X is a patent-protected prodrug-based anxiolytic formulation that are at the clinical stage for the safety, tolerability, pharmacodynamics and efficacy evaluation in human as an anxiolytic with a potential to treat other related affective disorders. MP-20X is a combination formulation, targets CB1/CB2/5-HT1A receptors and mGluR to exert anxiolytic effect by synergism that mitigates the side effects often inherent with first-line anxiolytics. MP-20X is delivered sublingually/transmucosally to ensure increased and consistent bioavailability across patients (bypassing first pass metabolism) while avoiding discomfort in patients who experience nausea and have difficulty swallowing or may vomit. Medipure’s goal is to avoid issues related to dependency and tolerance that exists in current anxiolytic medications on the market while ensuring optimal product safety and efficacy.